2024
GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis
He X, Hawkins C, Lawley L, Phan T, Park I, Joven N, Zhang J, Wunderlich M, Mizukawa B, Pei S, Patel A, VanOudenhove J, Halene S, Fang J. GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2024, 1871: 167565. PMID: 39522891, DOI: 10.1016/j.bbadis.2024.167565.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute myeloid leukemia cellsPro-survival pathwaysInhibiting isocitrate dehydrogenaseMetabolic symbiosisMyelodysplastic syndromeHematopoietic malignanciesExtracellular acidosisAssociated with inferior clinical outcomesCellular respirationFirst-line chemotherapeutic agentAcute myeloid leukemia patientsInferior clinical outcomesAerobic glycolysisCell survival in vitroEngraftment in vivoDecreased Ca<sup>2+</sup> levelDecreased aerobic glycolysisSurvival in vitroGlucose metabolic pathwaysG protein-coupled receptor 68Impacts chemosensitivityIn vitro observationsTumoricidal effectMyeloid leukemia
2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studiesCo-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genesCo-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, Delasos L, Hicks J, Aldea M, Minuti G, Hines J, Aredo J, Dennis M, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess J, Kim S, Goldberg S, Li M, Wang Q, Qing Y, Ni Y, Truong M, Lee R, Ricciuti B, Alessi J, Wang J, Resuli B, Landi L, Tseng S, Nishino M, Digumarthy S, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan A, Blumenschein G, Zhang J, Owen D, Blakely C, Mountzios G, Shu C, Bestvina C, Garassino M, Marrone K, Gray J, Patel S, Cummings A, Wakelee H, Wolf J, Scagliotti G, Cappuzzo F, Barlesi F, Patil P, Drusbosky L, Gibbons D, Meric-Bernstam F, Lee J, Heymach J, Hong D, Heist R, Awad M, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discovery 2023, 13: 1556-1571. PMID: 37068173, PMCID: PMC11024958, DOI: 10.1158/2159-8290.cd-22-1420.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerClinical outcomesPatient stratificationRas gene alterationsInferior clinical outcomesCell lung cancerEarly disease progressionPoor clinical outcomesTumor suppressor genePrognostic subgroupsCombination therapyInferior outcomesIndividual tumorsGene alterationsCo-mutationsClinical outcome predictionDNA damage response/repairLung cancerGenomic alterationsSuppressor geneDisease progressionInhibitor efficacyTreatment personalizationPatients
2021
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
Ernst M, Alaiwi S, Dizman N, Labaki C, Nuzzo P, Adib E, Schmidt A, Meza L, Gan C, Wells J, Bakouny Z, Pal S, Choueiri T, Heng D, Dudani S. The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). Journal Of Clinical Oncology 2021, 39: 4552-4552. DOI: 10.1200/jco.2021.39.15_suppl.4552.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOverall survivalABS exposureClinical outcomesTreatment failureResponse rateMultivariable analysisIndependent associationRisk factorsAdministration of AbFourth-line settingIMDC risk factorsIMDC risk scoresPoor-risk diseaseTreatment linesMultivariable Cox regressionInferior clinical outcomesInferior overall survivalIndependent prognostic markerRenal cell carcinomaSignificant independent associationOutcomes of interestIMDC criteriaCheckpoint inhibitors
2019
Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL
Kim E, Fan J, Bolen C, Bazeos A, Jiang Y, Balasubramanian S, Balakrishnan R, Knapp A, Humphrey K, Nielsen T, Venstrom J, Hernandez G, Paulson J. Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL. Blood 2019, 134: 2788. DOI: 10.1182/blood-2019-124687.Peer-Reviewed Original ResearchWhole-exome sequencingDiffuse large B-cell lymphomaExome-sequencing dataInternational Prognostic IndexBCL2 inhibitor venetoclaxHigh-risk groupRNA gene expression dataGene expression dataTargeted therapyClinical outcomesCopy number amplificationNext-generation sequencingDe novo diffuse large B-cell lymphomaAssociated with inferior clinical outcomesLarge B-cell lymphomaGenetic risk modelsNucleotide variantsAdverse prognostic impactClinical prognostic scoresB-cell lymphomaInferior clinical outcomesImprove survival outcomesExpression dataExome sequencingClinically heterogeneous diseaseMA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Skoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings A, Elamin Y, Lam V, Zhang J, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston R, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Lacroix L, Memmott R, Madrigal J, Goldman J, Lau S, Killam J, Walther Z, Carter B, Woodcock M, Roth J, Swisher S, Leighl N, Digumarthy S, Mooradian M, Rotow J, Wolf J, Scagliotti G, Planchard D, Besse B, Bivona T, Gandara D, Garon E, Rizvi N, Camidge D, Schalper K, Herbst R, Shaw A, Neal J, Wakelee H, Brahmer J, Jänne P, Carbone D, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach J. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal Of Thoracic Oncology 2019, 14: s294-s295. DOI: 10.1016/j.jtho.2019.08.591.Peer-Reviewed Original ResearchNon-squamous NSCLCInferior clinical outcomesClinical outcomesChemo-ImmunotherapyGenomic alterationsNSCLCPreoperative IDEAL (Iterative Decomposition of Echoes of Asymmetrical Length) magnetic resonance imaging rotator cuff muscle fat fractions are associated with rotator cuff repair outcomes
Lansdown DA, Morrison C, Zaid MB, Patel R, Zhang AL, Allen CR, Feeley BT, Ma CB. Preoperative IDEAL (Iterative Decomposition of Echoes of Asymmetrical Length) magnetic resonance imaging rotator cuff muscle fat fractions are associated with rotator cuff repair outcomes. Journal Of Shoulder And Elbow Surgery 2019, 28: 1936-1941. PMID: 31371160, DOI: 10.1016/j.jse.2019.05.018.Peer-Reviewed Original ResearchConceptsRotator cuff repairPostoperative PROMIS scoresPROMIS scoresFatty infiltrationCuff repairFat fractionRotator cuff muscle fatty infiltrationRotator cuff repair outcomesOnly significant independent predictorArthroscopic rotator cuff repairPreoperative fatty infiltrationInferior clinical outcomesSignificant independent predictorsIntramuscular fat fractionMuscle fatty infiltrationMuscle fat fractionMagnetic resonance imagingQuantitative magnetic resonance imagingMagnetic resonance imaging sequencePostoperative outcomesIndependent predictorsClinical outcomesTear sizePatientsResonance imaging
2018
Opioid dependency is independently associated with inferior clinical outcomes after trauma
Hsiang WR, McGeoch C, Lee S, Cheung W, Becher R, Davis KA, Schuster K. Opioid dependency is independently associated with inferior clinical outcomes after trauma. Injury 2018, 50: 192-196. PMID: 30342762, DOI: 10.1016/j.injury.2018.10.015.Peer-Reviewed Original ResearchConceptsNon-home dischargeOpioid-dependent patientsLength of stayInjury Severity ScoreOpioid dependencyVentilator daysMajor complicationsClinical outcomesPrescription abuseIllicit abuseLonger LOSChronic pain subgroupsMore ventilator daysOpioid-naïve patientsUse of opioidsAcademic Level IHigher readmission ratesInferior clinical outcomesChronic pain patientsOpioid subgroupsNaïve patientsAdult patientsPain subgroupsPatient demographicsReadmission rates
2012
Delayed graft function requiring more than one‐time dialysis treatment is associated with inferior clinical outcomes
Jayaram D, Kommareddi M, Sung R, Luan F. Delayed graft function requiring more than one‐time dialysis treatment is associated with inferior clinical outcomes. Clinical Transplantation 2012, 26: e536-e543. PMID: 23061763, DOI: 10.1111/ctr.12029.Peer-Reviewed Original ResearchConceptsDelayed graft functionIncidence of acute rejectionDelayed graft function patientsKidney transplant patientsClinical outcomesDialysis treatmentAcute rejectionTransplant patientsGraft functionComplication of deceased donor kidney transplantationDeceased donor kidney transplant patientsProlonged delayed graft functionAssociated with inferior clinical outcomesHigher incidence of acute rejectionSingle-center retrospective analysisAdult kidney transplant patientsEarly renal functionStudies of therapeutic approachesInferior clinical outcomesDeceased donor kidney transplantationDonor kidney transplantationKidney survivalDialysis requirementRenal functionPost-transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply